Treatment of GLP1 receptor agonists and body mass control

The prevalence of obesity continues to be increasing in all age groups in most countries of the European Union (EU). Many obese people have a history of several successful weight losses, but very few are able to maintain the weight loss over a longer period of time. Initiation of the GLP1 RA adminis...

Full description

Saved in:

Bibliographic Details
Published in:	Vnitřní lékar̆stvĭ Vol. 61; no. 4; p. 316
Main Authors:	Žák, Petr, Olšovský, Jindřich
Format:	Journal Article
Language:	Czech
Published:	Czech Republic 01-04-2015
Subjects:	Body Mass Index Diabetes Mellitus, Type 2 - drug therapy Glucagon-Like Peptide 1 - analogs & derivatives Humans Hypoglycemic Agents - therapeutic use Receptors, Glucagon - agonists Weight Loss
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The prevalence of obesity continues to be increasing in all age groups in most countries of the European Union (EU). Many obese people have a history of several successful weight losses, but very few are able to maintain the weight loss over a longer period of time. Initiation of the GLP1 RA administration during weight loss maintenance would inhibit weight loss-induced increases in soluble leptin receptor plasma concentrations resulting in higher level of free leptin thereby preventing weight regain. In contrast initiation of insulin treatment in type 2 diabetes patients is frequently accompanied with weight gain. The GLP1 administration results in HbA1c decrease accompanied with weight loss, presents attractive alternative to basal insulin. The question remains to be answered in the future, if the GLP1 RA administration is generally more frequently started in antiobese than antidiabetes implication.
ISSN:	0042-773X